Navigation Links
Creabilis Raises €15M ($20M) in Series B Fundraising Round
Date:10/4/2011

LUXEMBOURG, October 4, 2011 /PRNewswire/ --

Funds to Advance Development of Creabilis' First-in-Class Products

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors, joined the round. The new funds will be used to finance the development of the company's first-in-class treatments, including its lead product CT327 to the end of phase II.

CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis' Low Systemic Exposure (LSE) technology. Positive efficacy of CT327 has been seen in two Phase IIa studies, in both psoriasis and atopic dermatitis, in which CT327 was well tolerated and demonstrated a good safety profile. CT327 is also in development for the treatment of pain, with proof-of-concept trials currently underway.

The company's pipeline also includes CT637, a new approach to the treatment of significant inflammatory and autoimmune conditions and CT340, a potent TrkA kinase inhibitor that has therapeutic potential in a broad range of inflammatory conditions. CT637 and CT340 are anticipated to reach Investigational New Drug application (IND) stage of development in early 2012.

Dr Eliot Forster CEO of Creabilis said: "This new funding reflects the medical importance and significant commercial potential of our drugs pipeline. In Abbott Biotech Ventures, we have added another leading life science investor into the Company. Their involvement, and the ongoing support of our existing investors, demonstrates their confidence in the Company and in our ability to drive our projects forward."

For further information please contact:


Creabilis
Eliot Forster
eforster@creabilis-sa.com
Creabilis SA
5 rue Jean Monnet L-2810 LUXEMBOURG
                   
Citigate Dewe Rogerson
Chris Gardner or Nina Enegren
Tel: +44(0)20-7282-1050
E-mail: nina.enegren@citigatedr.co.uk

About Creabilis SA

Creabilis is a clinical-stage European biotechnology company creating innovative new drugs to tackle unmet medical needs in dermatology and inflammatory diseases. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of its target diseases.

Creabilis' lead product is CT327 a novel topically applied TrkA kinase inhibitor developed using the Company's Low Systemic Exposure (LSE) technology. CT327 is currently in Phase II clinical trials in psoriasis and atopic dermatitis and is undergoing proof-of-concept studies in pain. CT340 is a potent TrkA kinase inhibitor under development for the treatment of conditions in which TrkA kinase inhibition is indicated, including inflammatory arthritis, and pain. The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions, such as rheumatoid arthritis. Earlier-stage projects include a number of highly promising candidates for dermatological and wider indications.

Creabilis is backed by some of Europe's most highly respected life sciences investors including Sofinnova Partners, Neomed and Abbott Biotech Ventures.

For more information, please visit:  http://www.creabilis-sa.com



'/>"/>
SOURCE Creabilis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Creabilis Appoints Dr David Roblin as Chief Medical Officer
2. Creabilis Expands Senior Management Team
3. Bacon Eating Contest Raises Money for American Heart Association
4. Proteolix Raises $79 Million in Series C Financing
5. Yongye Biotechnology International Raises $9.4 Million in Private Placement
6. MacroGenics Raises $25M in Series D-2 Financing
7. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
8. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
9. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
10. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
11. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Biocom, the association representing the Southern ... San Diego companies to ... Medicine Advocacy Fly-In. Biocom Fly-In participants had the opportunity to ... the Centers for Medicare and Medicaid Services (CMS), the National ... Representatives Susan Davis and Scott Peters ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Georgia World Congress Center in Atlanta, Georgia, will include 848 exhibitors (count as ... companies will be displaying products and services used by the scientific community in ...
(Date:2/12/2016)... , Feb. 12, 2016  BD (Becton, Dickinson and ... technology company, today announced the launch of the BD ... and Technology (AGBT) Meeting. --> ... genomic research by providing cost effective NGS library preparation ... a high-throughput, fully integrated, next generation sequencing (NGS) library ...
(Date:2/12/2016)... PLAINFIELD, N.J. , Feb. 12, 2016 /PRNewswire/ ... announced the second annual STRIVE (Strategies to Realize ... Duchenne muscular dystrophy (DMD). STRIVE provides funds to ... programs that will make meaningful contributions to the ... or fostering development of future patient advocates. ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
Breaking Biology News(10 mins):